BioCryst Pharmaceuticals (BCRX) : Rtw Investments scooped up 1,967,513 additional shares in BioCryst Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 4,204,579 shares of BioCryst Pharmaceuticals which is valued at $23,882,009.BioCryst Pharmaceuticals makes up approximately 7.51% of Rtw Investments’s portfolio.
Other Hedge Funds, Including , Deerfield Management Co added BCRX to its portfolio by purchasing 4,401,846 company shares during the most recent quarter which is valued at $25,002,485. BioCryst Pharmaceuticals makes up approx 1.42% of Deerfield Management Co’s portfolio.Proshare Advisors reduced its stake in BCRX by selling 10,106 shares or 15.83% in the most recent quarter. The Hedge Fund company now holds 53,737 shares of BCRX which is valued at $272,447.Blackrock Investment Management boosted its stake in BCRX in the latest quarter, The investment management firm added 17,000 additional shares and now holds a total of 295,020 shares of BioCryst Pharmaceuticals which is valued at $1,324,640.
BioCryst Pharmaceuticals opened for trading at $5.89 and hit $5.9967 on the upside on Monday, eventually ending the session at $5.98, with a gain of 2.05% or 0.12 points. The heightened volatility saw the trading volume jump to 5,89,055 shares. Company has a market cap of $441 M.
On the company’s financial health, BioCryst Pharmaceuticals reported $-0.16 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Nov 7, 2016. Analyst had a consensus of $-0.26. The company had revenue of $7.80 million for the quarter, compared to analysts expectations of $5.34 million. The company’s revenue was down -29.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.20 EPS.
BioCryst Pharmaceuticals Inc. (BioCryst) is a biotechnology company. The Company designs optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB BCX4161 BCX7353 and other second generation HAE compounds BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza in the United States as RAPIVAB in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.